Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer
Verified date | February 2016 |
Source | Genentech, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
Status | Completed |
Enrollment | 1145 |
Est. completion date | November 2014 |
Est. primary completion date | November 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed Informed Consent Form - Histologically or cytologically confirmed NSCLC - Advanced NSCLC or recurrent disease - INR no greater than 1.3 and aPTT no greater than upper limits of normal (ULN) within 28 days prior to enrollment for subjects not on low molecular weight heparin or fondaparinux. Subjects on low molecular weight heparin or fondaparinux are not required to meet INR or aPTT limits. Chronic full-dose anticoagulation with warfarin is not permitted. - 18 years of age or older - For women of childbearing potential and sexually active men, use of an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to enrollment and for the duration of the study Exclusion Criteria: - Prior systemic chemotherapy in the metastatic setting - Treatment with an investigational or marketed agent that acts by either EGFR inhibition or anti-angiogenesis mechanisms - Pregnancy or lactation - Any other medical condition, including mental illness or substance abuse, deemed by the clinician to be likely to interfere with a subject's ability to provide informed consent, cooperate, and participate in the study, or to interfere with the interpretation of the results - Active infection or a fever within 3 days of enrollment - Active malignancy other than lung cancer - Radiation therapy to sites other than whole brain within 14 days prior to enrollment - History of gross hemoptysis within 3 months prior to enrollment - Known hypersensitivity to any of the components of cytotoxic chemotherapy combinations, bevacizumab, or tyrosine kinase inhibitors - Inadequately controlled hypertension - Unstable angina or New York Heart Association Grade II or greater CHF - Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrollment - History of myocardial infarction within 6 months prior to enrollment - History of stroke within 6 months prior to enrollment - Symptomatic peripheral vascular disease within 6 months prior to enrollment - Evidence of bleeding diathesis or coagulopathy - Serious, non-healing wound, ulcer, or bone fracture - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment; anticipation of need for major surgical procedure during the course of the study - Current, recent, or planned participation in an experimental drug study other than this Genentech-sponsored bevacizumab/erlotinib study - Progressive neurologic symptoms in subjects with a history of brain metastases - History of significant vascular disease (e.g., aortic aneurysm) |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Argentina | CEMIC | Buenos Aires | |
Argentina | Hospital Britanico | Buenos Aires | |
Argentina | Hospital Pirovano | Buenos Aires | |
Argentina | Hospital Toru | Buenos Aires | |
Argentina | Centro Oncologico de Cordoba | Cordoba | |
Argentina | COIR | Mendoza | |
Argentina | Instituto Medico Privado | Resistencia | |
Argentina | Clinica Oncologica de Rosario | Rosario | |
Argentina | ISIS Clinica Especializada | Sante Fe | |
Australia | Holy Spirit Hospital Northside | Chermside, QLD | |
Australia | Sunshine Coast Cancer Centre | Nambour, QLD | |
Australia | Sir Charles Gairdner Hospital | Nedlands, WA | |
Australia | Burnside War Memorial Hospital | Toorak Gardens, SA | |
Belgium | Cliniques Univ St Luc | Brussels | |
Belgium | CHR Citadelle Liege | Liege | |
Brazil | Instituto Nacional do Cancer | Rio de Janeiro | |
Brazil | Hospital Das Clinicas | Sao Paulo | |
Brazil | Instituto de cancer Arnaldo | Sao Paulo | |
Bulgaria | Regional Oncodispensary | Plovdiv | |
Bulgaria | Regional Oncodispensary | Rousse | |
Bulgaria | Regional Oncodispensary | Shoumen | |
Bulgaria | National Specialized Hospital | Sofia | |
Bulgaria | Regional Oncodispensary | Sofia | |
Bulgaria | UMHAT "Queen Joanna" | Sofia | |
Bulgaria | Regional Oncodispensary | Stara Zagora | |
Bulgaria | MHAT "St Marina" | Varna | |
Bulgaria | Regional Oncodispensary | Veliko Tarnovo | |
Hong Kong | Princess Margaret Hospital | Hong Kong | |
Hong Kong | Queen Elizabeth Hospital | Hong Kong | |
Hong Kong | Queen Mary Hospital | Hong Kong | |
Hong Kong | Tuen Mun Hospital | Hong Kong | |
Israel | Hadassah Medical Center | Jerusalem | |
Israel | Sourasky Medical Center | Tel-Aviv | |
Israel | Sheba Medical Center | Tel-Hashomer | |
Italy | Azienda Ospedaliera Univ | Genova | |
Italy | Ist Nazion per Ricerca Cancro | Genova | |
Italy | Univ degli Studi di Napoli | Napoli | |
Italy | Azienda Ospedaliera | Parma | |
Italy | Azienda Osper di Perugia | Perugia | |
Italy | Divisione Onc Med dell'Azienda | Udine | |
Mexico | Torre Medica Cristobal Colon | Acapulco | |
Mexico | Inst Nacional de Cancerologia | Distrito Federal | |
Mexico | ISSSTE Merida | Merida | |
Mexico | Hospital de Especialidades | Torreon, Coahuila | |
Philippines | Perpetual Succour Hospital | Cebu City | Visayas |
Philippines | Philippine General Hospital | Manila | Luzon |
Philippines | Univ of Santo Tomas Hospital | Manila | |
Philippines | The Medical City | Pasig City | Luzon |
Philippines | St Luke's Medical Center | Quezon City | |
Philippines | Veterans Memorial Medical Ctr | Quezon City | Luzon |
Romania | Centrul de Onc Medical Lasi | Iasi | |
Romania | Spitalul Clinic Judetean Sibiu | Sibiu | |
Romania | Spitalul Judetean de Urgente | Suceava | |
Singapore | National Cancer Center | Singapore | |
Spain | Hospital de Cruces | Barakaldo | |
Spain | Hospital Clinic i Provincial | Barcelona | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Universitario | La Laguna | |
Spain | Corporacio Sanitaria Parc | Sabadell | Barcelona |
Spain | Hospital Clinico Universitario | Valencia | |
Spain | Instituto Valenciano Oncologia | Valencia | |
Taiwan | China Medical Univ Hosp | Taichung | |
Taiwan | National Taiwan University | Taipei | |
Taiwan | Taichung Veterans Gen Hosp | Taiwan | |
Thailand | Bumrungrad International Hosp | Bangkok | |
Thailand | National Cancer Institute | Bangkok | |
Thailand | Pramongkutklao Hospital | Bangkok | |
Thailand | Siriraj Hospital | Bangkok | |
Thailand | Maharaj Nakorn Chiang Mai Hosp | Chiangmai | |
United Kingdom | Bristol Heamatology & Onc Ctr | Bristol | |
United States | Akron General Medical Center | Akron | Ohio |
United States | Summa Health System | Akron | Ohio |
United States | Phoebe Putney Cancer Center | Albany | Georgia |
United States | Central Hem/Onc Medical Group | Alhambra | California |
United States | Chicagoland Hematology Onc | Arlington Heights | Illinois |
United States | Northeast Georgia Cancer Care | Athens | Georgia |
United States | Lone Star Oncology Consultants | Austin | Texas |
United States | Comp Blood & Cancer Center | Bakersfield | California |
United States | H&J Weinberg Cancer Institute | Baltimore | Maryland |
United States | SW Vermont Healthcare Onc Asoc | Bennington | Vermont |
United States | Hematology Oncology Associates | Bettendorf | Iowa |
United States | Billings Clinic | Billings | Montana |
United States | Center for Hematology-Oncology | Boca Raton | Florida |
United States | Caritas St. Elizabeth Med Ctr | Boston | Massachusetts |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Zale P Bernstein MD - PP | Buffalo | New York |
United States | Lahey Clinic Med Ctr | Burlington | Massachusetts |
United States | South Bay Oncology | Campbell | California |
United States | Aultman Hospital | Canton | Ohio |
United States | Gabrail Cancer Center | Canton | Ohio |
United States | Charleston Cancer Center | Charleston | South Carolina |
United States | Presbyterian Hospital | Charlotte | North Carolina |
United States | Erlanger Health Systems | Chattanooga | Tennessee |
United States | Ctr for Cancer & Hem Disease | Cherry Hill | New Jersey |
United States | Weiss-Strauss Oncology Center | Chicago | Illinois |
United States | Onc/Hem Care Clin Trials LLC | Cincinnati | Ohio |
United States | MetroHealth Medical Center | Cleveland | Ohio |
United States | Oncology Hematology Associates | Clinton | Maryland |
United States | Vermont Ctr Cancer Medicine | Colchester | Vermont |
United States | Ellis Fischel Cancer Center | Columbia | Missouri |
United States | Maryland Oncology/Hema PA | Columbia | Maryland |
United States | Mid Ohio Onc Hematology Inc | Columbus | Ohio |
United States | Riverside Methodist Hospital | Columbus | Ohio |
United States | Bay Area Cancer Research Grp | Concord | California |
United States | NorthEast Medical Center | Concord | North Carolina |
United States | Bassett Cancer Center | Cooperstown | New York |
United States | Coastal Bend Cancer Center | Corpus Christi | Texas |
United States | Texas Cancer Associates | Dallas | Texas |
United States | Texas Hematology Oncology | Dallas | Texas |
United States | Dayton Clinical Oncology Prog | Dayton | Ohio |
United States | Halifax Medical Center | Daytona Beach | Florida |
United States | Mile High Oncology | Denver | Colorado |
United States | Pacific Onc & Hem Assoc | Encinitas | California |
United States | Forte, Attas & Schleider | Englewood | New Jersey |
United States | Ephrata Cancer Center | Ephrata | Pennsylvania |
United States | San Juan Onco Assoc | Farmington | New Mexico |
United States | Hunterdon Medical Center | Flemington | New Jersey |
United States | Front Range Cancer Specialists | Fort Collins | Colorado |
United States | JPS Center for Cancer Care | Fort Worth | Texas |
United States | Pacific Coast Hem/Onc | Fountain Valley | California |
United States | Metrowest Cancer Center | Framingham | Massachusetts |
United States | Frederick Memorial Hospital | Frederick | Maryland |
United States | Central State Medical Center | Freehold | New Jersey |
United States | Cancer Care Associates | Fresno | California |
United States | St. Edward Mercy Medical Ctr | Ft Smith | Arizona |
United States | St. Jude Heritage Med Group | Fullerton | California |
United States | Univ of Texas Medical Branch | Galveston | Texas |
United States | LaGrange Oncology Associates | Geneva | Illinois |
United States | The Jones Clinic | Germantown | Tennessee |
United States | Ronald H. Yanagihara | Gilroy | California |
United States | Adriondack Cancer Care | Glen Falls | New York |
United States | Glendale Adventist Medical Ctr | Glendale | California |
United States | Oncology Alliance | Glendale | Wisconsin |
United States | Spectrum Health | Grand Rapids | Michigan |
United States | Big Sky Oncology | Great Falls | Montana |
United States | BRANY | Great Neck | New York |
United States | Moses Cone Reg Cncr Ctr | Greensboro | North Carolina |
United States | Emerywood Hematology Oncology | High Point | North Carolina |
United States | Gajera & Patel, PLLC | Hopkinsville | Kentucky |
United States | Carolina BioOncology Institute | Huntersville | North Carolina |
United States | Univ Physicians Internal Med | Huntington | West Virginia |
United States | Florida Wellcare Alliance | Inverness | Florida |
United States | Jackson-Madsion County Hosp | Jackson | Tennessee |
United States | Baptist Cancer Institute | Jacksonville | Florida |
United States | Queens Cancer Center | Jamaica | New York |
United States | Freeman Cancer Institute | Joplin | Missouri |
United States | Kalamazoo Hem & Onc | Kalamazoo | Michigan |
United States | Kinston Medical Specialists | Kinston | North Carolina |
United States | Cascade Cancer Center | Kirkland | Washington |
United States | Armstrong County Memorial Hosp | Kittanning | Pennsylvania |
United States | Scipps Clinic | La Jolla | California |
United States | Wilford Hall Medical Center | Lackland AFB | Texas |
United States | La Grange Oncology Associates | Lagrange | Illinois |
United States | Hem Onc Assoc Phys Lancaster | Lancaster | Pennsylvania |
United States | Comp Cancer Centers of Nevada | Las Vegas | Nevada |
United States | Suburban Hem-Onc Associates | Lawrenceville | Georgia |
United States | NE Hematology Oncology, PC | Lincoln | Nebraska |
United States | St. Barnabas Health Care Sys | Livingston | New Jersey |
United States | Loma Linda Univ Medical Center | Loma Linda | California |
United States | Pacific Shores Medical Group | Long Beach | California |
United States | Kenmar Research Institute LLC | Los Angeles | California |
United States | UCLA Medical Ctr | Los Angeles | California |
United States | Consultants in Blood Disorders | Louisville | Kentucky |
United States | Kentuckiana Cancer Center | Louisville | Kentucky |
United States | University of Louisville | Louisville | Kentucky |
United States | Dean Clinic | Madison | Wisconsin |
United States | Ohio Cancer Specialists | Mansfield | Ohio |
United States | Northwest Georgia Onc Centers | Marietta | Georgia |
United States | Marquette General Health Sys | Marquette | Michigan |
United States | Clopton Clinic | Memphis | Tennessee |
United States | Jackson Memorial Hospital | Miami | Florida |
United States | Crystal Run Health Care | Middletown | New York |
United States | Signal Point Hem/Oncology Inc | Middletown | Ohio |
United States | Medical Consultants LTD | Milwaukee | Wisconsin |
United States | Virginia Piper Cancer Inst | Minneapolis | Minnesota |
United States | Montana Cancer Specialists | Missoula | Montana |
United States | Sacred Heart Medical Onc Group | Mobile | Alabama |
United States | Sutter Gould Med Foundation | Modesto | California |
United States | Mountainside Hospital | Montclair | New Jersey |
United States | West Virginia University | Morgantown | West Virginia |
United States | Morristown Memorial Hospital | Morristown | New Jersey |
United States | Hematology Oncology Assoc SJ | Mount Holly | New Jersey |
United States | Community Hospital | Munster | Indiana |
United States | Sarah Cannon Cancer Center | Nashville | Tennessee |
United States | Vanderbilt University Medical | Nashville | Tennessee |
United States | Jersey Shore Medical Center | Neptune | New Jersey |
United States | Cancer Institute of New Jersey | New Brunswick | New Jersey |
United States | Mem Sloan Kettering Cancer Ctr | New York | New York |
United States | NYU Medical Center | New York | New York |
United States | Peninsula Cancer Institute | Newport News | Virginia |
United States | North Valley Hem Onc Med Grp | Northridge | California |
United States | Associates in Medical Oncology | Oak Lawn | Illinois |
United States | Nebraska Methodist Hospital | Omaha | Nebraska |
United States | Hem Onc Med Grp Orange Cty | Orange | California |
United States | Medical Oncology Care Assoc | Orange | California |
United States | Mid-Florida Hem Oncology Ctr | Orange City | Florida |
United States | Integrated Comm Onc Network | Orange Park | Florida |
United States | Owensboro Medical Health Sys | Owensboro | Kentucky |
United States | Ventura Co Hem-Onc Specialists | Oxnard | California |
United States | The Valley Hospital | Paramus | New Jersey |
United States | Onc Hem Assoc of Central IL | Peoria | Illinois |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Wilshire Oncology Medical Grp | Pomona | California |
United States | St. Joseph Mercy Oakland | Pontiac | Michigan |
United States | Hematology Onc Treasure Coast | Port Saint Lucie | Florida |
United States | Providence Portland Med Center | Portland | Oregon |
United States | All Saints Cancer Center | Racine | Wisconsin |
United States | West Suburban Cancer Center | River Forest | Illinois |
United States | SW Virginia Hem Onc | Roanoke | Virginia |
United States | OSF St. Anthony Med Ctr | Rockford | Illinois |
United States | William Beaumont Hospital | Royal Oak | Michigan |
United States | Community Cancer Center | Rutland | Vermont |
United States | Mercy General Hospital | Sacramento | California |
United States | Sutter Cancer Center | Sacramento | California |
United States | St. Louis Univ Care Center | Saint Louis | Missouri |
United States | Los Palos Oncology & Hem | Salinas | California |
United States | Kaiser Permanente | San Diego | California |
United States | Naval Medical Center | San Diego | California |
United States | Pacific Hematology Oncology | San Francisco | California |
United States | Kaiser Permanente Santa Teresa | San Jose | California |
United States | Sansum Medical Clinic, Inc. | Santa Barbara | California |
United States | Santa Barbara Hem Onc Med Grp | Santa Barbara | California |
United States | Central Coast Medical Oncology | Santa Maria | California |
United States | The Angeles Clinic | Santa Monica | California |
United States | Redwood Regional Med Grp | Santa Rosa | California |
United States | Mayo Clinic | Scottsdale | Arizona |
United States | Scranton Hematology Oncology | Scranton | Pennsylvania |
United States | Willis-Knighton Cancer Center | Shreveport | Louisiana |
United States | Siouxland Hem-Onc Assoc LLP | Sioux City | Iowa |
United States | Palmetto Hematology Oncology | Spartanburg | South Carolina |
United States | Baystate Medical Center | Springfield | Massachusetts |
United States | Missouri Cancer Center, PC | St Charles | Missouri |
United States | Overlook Hospital | Summit | New Jersey |
United States | SUNY Upstate | Syracuse | New York |
United States | Northwest Medical Specialists | Tacoma | Washington |
United States | Holy Name Hospital | Teaneck | New Jersey |
United States | Providence Medical Group | Terre Haute | Indiana |
United States | Toledo Community Hospital | Toledo | Ohio |
United States | Cancer Care Associates | Torrance | California |
United States | Arizona Cancer Center | Tucson | Arizona |
United States | Assoc in Hematology Oncology | Upland | Pennsylvania |
United States | Arch Medical Services | Washington | Missouri |
United States | Beaufort County Hospital | Washington | North Carolina |
United States | Washington Onc Hem Center PC | Washington | District of Columbia |
United States | Covenant Clinic | Waterloo | Iowa |
United States | Lankenau Medical Office Bldg | Wynnewood | Pennsylvania |
United States | Forum Health Cancer Care Ctr | Youngstown | Ohio |
Lead Sponsor | Collaborator |
---|---|
Genentech, Inc. |
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Hong Kong, Israel, Italy, Mexico, Philippines, Romania, Singapore, Spain, Taiwan, Thailand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival (PFS) | PFS was defined as the length of time from randomization until documented disease progression or death from any cause, whichever occurred earlier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Data presented until cut-off date 18 July 2008. | Approximately 3 years | No |
Secondary | Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Chemotherapy Phase | Treatment-emergent adverse events were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.. Number of participants who had Grade >=3TEAEs of pulmonary hemorrhage, gastrointestinal (GI) perforation, arterial thromboembolic (ATE) events, proteinuria, congestive heart failure (CHF), and hypertension were presented. Data presented up to data cutoff 18 July 2008. | Approximately 3 years | No |
Secondary | Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Post-Chemotherapy Phase | Treatment-related adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state and are judged by the investigator to be possibly, probably or definitely related to study medication. Pulmonary hemorrhage, GI perforation, ATE events, proteinuria, CHF, and hypertension were prospectively identified TEAEs of grade >=3. | Approximately 3 years | No |
Secondary | Number of Participants With Any Adverse Events During Post-Chemotherapy Phase | An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event. Data presented up to data cutoff 19 June 2009. | Approximately 3.5 years | No |
Secondary | Incidence of Study Treatment Discontinuation for Reasons Other Than Disease Progression in Chemotherapy Phase | Participants who experienced disease progression were discontinued from the study. Data presented up to data cutoff (18 July 2008). | Approximately 3 years | No |
Secondary | Incidence of Study Treatment Discontinuation | Participants in post-chemotherapy phase were discontinued from the study for the reasons other than disease progression. Data presented Up to data cutoff 18 July 2008. | Approximately 3 years | No |
Secondary | Overall Survival | Overall survival was defined as the length of time from randomization to death. | Approximately 3.5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |